— Know what they know.
Not Investment Advice

MRTX NASDAQ

Mirati Therapeutics, Inc.
1W: -0.5% 1M: -0.4% 3M: +5.4% 1Y: +28.6% 3Y: -72.4% 5Y: -9.6%
$58.70
Last traded 2024-01-23 — delisted
NASDAQ · Healthcare · Biotechnology · $4.1B mcap · 39M float · 4.53% daily turnover

Balance Sheet Trends

Total Assets
$1.2B -24.3% ▼
5Y CAGR: +50.2%
Total Liabilities
$206M +7.5% ▲
5Y CAGR: +71.3%
Shareholders Equity
$997M -28.7% ▼
5Y CAGR: +47.4%
Cash & Investments
$1.1B -27.3% ▼
5Y CAGR: +48.4%
Total Debt
$52M +12.3% ▲
Net Debt
-$184M +50.0% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2018FY2019FY2020FY2021FY2022
— Assets —
Cash$223M$415M$1.4B$413M$235M
Short-Term Investments$0$0$0$1.1B$849M
Cash & ST Investments$223M$415M$1.4B$1.5B$1.1B
Net Receivables$768K$2M$0$0$865K
Inventory-$768K-$2M-$2M-$3M$3M
Other Current Assets$4M$9M$14M$17M$21M
Total Current Assets$227M$424M$1.4B$1.5B$1.1B
Property, Plant & Equip.$473K$2M$48M$54M$54M
Goodwill & Intangibles$0$0$0$0$15M
Long-Term Investments$0$0$16M$8M$3M
Other Non-Current Assets$1M$6M$9M$19M$22M
Total Non-Current Assets$2M$8M$72M$81M$94M
Total Assets$228M$432M$1.5B$1.6B$1.2B
— Liabilities —
Accounts Payable$26M$48M$18M$35M$39M
Short-Term Debt$0$0$0$0$8M
Deferred Revenue$371K$824K$0-$1M$0
Other Current Liabilities$0$0$53M$108M$113M
Total Current Liabilities$26M$49M$71M$144M$159M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$44M$48M$47M
Total Non-Current Liabilities$732K$999K$44M$48M$47M
Total Liabilities$27M$50M$115M$192M$206M
— Equity —
Common Stock$33K$40K$50K$55K$58K
Retained Earnings-$559M-$772M-$1.1B-$1.7B-$2.5B
Accumulated OCI$9M$10M$10M$9M-$4M
Total Stockholders Equity$202M$382M$1.4B$1.4B$997M
Total Liabilities & Equity$228M$432M$1.5B$1.6B$1.2B
— Key Metrics —
Total Debt$0$0$42M$46M$52M
Net Debt-$223M-$415M-$1.3B-$367M-$184M
Total Investments$0$0$16M$1.1B$849M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms